Teleflex (NYSE:TFX) shares surged 9.74% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year outlook. The medical technology company significantly outperformed analyst expectations, demonstrating robust growth and improved profitability.
For the second quarter, Teleflex reported adjusted earnings per share of $3.73, handily beating the analyst consensus estimate of $3.36 by 11.04%. This represents a 9.06% increase from the $3.42 per share earned in the same period last year. Revenue for the quarter came in at $780.889 million, surpassing the analyst estimate of $771.477 million by 1.22% and marking a 4.16% year-over-year growth.
Buoyed by its strong performance, Teleflex raised its full-year 2025 guidance. The company now projects revenue growth of 9-10% for the year, up from its previous forecast. Additionally, Teleflex increased its outlook for full-year adjusted earnings per share from continuing operations to a range of $13.90-$14.30. This positive revision in the company's financial outlook, coupled with its better-than-expected quarterly results, appears to be the primary driver behind the significant pre-market stock price surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.